InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for five new non-executive employees. The Compensation Committee approved a total of 88,324 shares of restricted stock under the company's 2024 Inducement Plan.

The grants, made outside the company's 2021 Equity Incentive Plan, have a grant date of September 24, 2025. The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.

MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five (5) new non-executive employees in the aggregate amount of 88,324 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of September 24, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants were granted under the InspireMD’s 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including expectations regarding U.S. commercial launch and expansion. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at https://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com

FAQ

What inducement grants did InspireMD (NSPR) announce in September 2025?

InspireMD announced inducement grants of 88,324 shares of restricted stock to five new non-executive employees under their 2024 Inducement Plan.

What is the vesting schedule for InspireMD's September 2025 inducement grants?

The restricted stock vests over three years, with one-third vesting after the first year and the remaining two-thirds vesting equally on the second and third anniversaries.

Why did InspireMD issue these inducement grants in 2025?

The grants were issued as an inducement material to new non-executive employees entering employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

How does InspireMD's 2024 Inducement Plan differ from their 2021 Equity Incentive Plan?

The 2024 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously InspireMD employees, while the 2021 Equity Incentive Plan is their general equity compensation plan.